Abstract:Background and Aim: More than half of the small-molecule kinase inhibitors (KIs) induced liver injury clinically. Meanwhile, studies have shown a close relationship between mitochondrial damage and drug-induced liver injury (DILI). We aimed to study KIs and the binding between drugs and mitochondrial proteins to find factors related to DILI occurrence. Methods: A total of 1,223 oral FDA-approved drugs were collected and analyzed, including 44 KIs. Fisher’s exact test was used to analyze DILI potential and risk of different factors. A total of 187 human mitochondrial proteins were further collected, and high-throughput molecular docking was performed between human mitochondrial proteins and drugs in the data set. The molecular dynamics simulation was used to optimize and evaluate the dynamic binding behavior of the selected mitochondrial protein/KI complexes. Results: The possibility of KIs to produce DILI is much higher than that of other types (OR = 46.89, p = 9.28E-13). A few DILI risk factors were identified, including molecular weight (MW) between 400 and 600, the defined daily dose (DDD) ≥ 100 mg/day, the octanol–water partition coefficient (LogP) ≥ 3, and the degree of liver metabolism (LM) more than 50%. Drugs that met this combination of rules were found to have a higher DILI risk than controls (OR = 8.28, p = 4.82E-05) and were more likely to cause severe DILI (OR = 8.26, p = 5.06E-04). The docking results showed that KIs had a significant higher affinity with human mitochondrial proteins ( p = 4.19E-11) than other drug types. Furthermore, the five proteins with the lowest docking score were selected for molecular dynamics simulation, and the smallest fluctuation of the backbone RMSD curve was found in the protein 5FS8/KI complexes, which indicated the best stability of the protein 5FS8 bound to KIs. Conclusions: KIs were found to have the highest odds ratio of causing DILI. MW was significantly related to the production of DILI, and the average docking scores of KI drugs were found to be significantly different from other classes. Further analysis identified the top binding mitochondrial proteins for KIs, and specific binding sites were analyzed. The optimization of molecular docking results by molecular dynamics simulation may contribute to further studying the mechanism of DILI.

Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases

A serum metabonomics study on drug induced liver injury by UPLC coupled with Q-TOF mass spectrometry

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

Identification of Drug-Induced Liver Injury Biomarkers from Multiple Microarrays Based on Machine Learning and Bioinformatics Analysis

Association of Cytokines with Clinical Indicators in Patients with Drug-Induced Liver Injury

Proteomic Identification of Potential Susceptibility Factors in Drug-Induced Liver Disease.

Severe Drug-Induced Liver Injury From Over-the-Counter Medication

Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world

Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study

MicroRNAs in Drug-induced Liver Injury.

Qualified kidney injury biomarkers demonstrate value during early clinical drug development

Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI)

Study on the Characteristics of Small-Molecule Kinase Inhibitors-Related Drug-Induced Liver Injury

Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease

Salivary metabolites are promising noninvasive biomarkers of drug-induced liver injury

A Panel Of Serum Micrornas As Specific Biomarkers For Diagnosis Of Compound- And Herb-Induced Liver Injury In Rats

[Research Progress on Laboratory Diagnosis of Drug-Induced Liver Injury].